Calcium and Nuclear Signaling in Prostate Cancer
- PMID: 29671777
- PMCID: PMC5979488
- DOI: 10.3390/ijms19041237
Calcium and Nuclear Signaling in Prostate Cancer
Abstract
Recently, there have been a number of developments in the fields of calcium and nuclear signaling that point to new avenues for a more effective diagnosis and treatment of prostate cancer. An example is the discovery of new classes of molecules involved in calcium-regulated nuclear import and nuclear calcium signaling, from the G protein-coupled receptor (GPCR) and myosin families. This review surveys the new state of the calcium and nuclear signaling fields with the aim of identifying the unifying themes that hold out promise in the context of the problems presented by prostate cancer. Genomic perturbations, kinase cascades, developmental pathways, and channels and transporters are covered, with an emphasis on nuclear transport and functions. Special attention is paid to the molecular mechanisms behind prostate cancer progression to the malignant forms and the unfavorable response to anti-androgen treatment. The survey leads to some new hypotheses that connect heretofore disparate results and may present a translational interest.
Keywords: calcium; metastasis; myosin IC; nuclear import; prostate cancer.
Conflict of interest statement
The authors declare no conflict of interest. The funding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.
Similar articles
-
Fatty Acids and Calcium Regulation in Prostate Cancer.Nutrients. 2018 Jun 19;10(6):788. doi: 10.3390/nu10060788. Nutrients. 2018. PMID: 29921791 Free PMC article. Review.
-
The ZnR/GPR39 interacts with the CaSR to enhance signaling in prostate and salivary epithelia.J Cell Physiol. 2014 Jul;229(7):868-77. doi: 10.1002/jcp.24514. J Cell Physiol. 2014. PMID: 24264723
-
Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization.Mol Endocrinol. 2006 Mar;20(3):503-15. doi: 10.1210/me.2005-0351. Epub 2005 Nov 10. Mol Endocrinol. 2006. PMID: 16282370
-
Myosins in the Nucleus.Adv Exp Med Biol. 2020;1239:199-231. doi: 10.1007/978-3-030-38062-5_10. Adv Exp Med Biol. 2020. PMID: 32451861 Review.
-
In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis.Oncogene. 2002 Apr 18;21(17):2679-94. doi: 10.1038/sj.onc.1205352. Oncogene. 2002. PMID: 11965541
Cited by
-
The Anti-tumoral Properties of Orexin/Hypocretin Hypothalamic Neuropeptides: An Unexpected Therapeutic Role.Front Endocrinol (Lausanne). 2018 Sep 27;9:573. doi: 10.3389/fendo.2018.00573. eCollection 2018. Front Endocrinol (Lausanne). 2018. PMID: 30319552 Free PMC article. Review.
-
The Interplay of Dysregulated pH and Electrolyte Imbalance in Cancer.Cancers (Basel). 2020 Apr 7;12(4):898. doi: 10.3390/cancers12040898. Cancers (Basel). 2020. PMID: 32272658 Free PMC article. Review.
-
New Insights and Emerging Therapeutic Approaches in Prostate Cancer.Front Endocrinol (Lausanne). 2022 Feb 11;13:840787. doi: 10.3389/fendo.2022.840787. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35222290 Free PMC article. Review.
-
Glyoxalase System in Breast and Ovarian Cancers: Role of MEK/ERK/SMAD1 Pathway.Biomolecules. 2024 May 15;14(5):584. doi: 10.3390/biom14050584. Biomolecules. 2024. PMID: 38785990 Free PMC article. Review.
-
Progression-free survival of prostate cancer patients is prolonged with a higher regucalcin expression in the tumor tissues: Overexpressed regucalcin suppresses the growth and bone activity in human prostate cancer cells.Transl Oncol. 2021 Jan;14(1):100955. doi: 10.1016/j.tranon.2020.100955. Epub 2020 Nov 21. Transl Oncol. 2021. PMID: 33232921 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical